Standard vs High-Dose Cytarabine With or Without Vorinostat for Previously Untreated AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
Leukemia 2023 Nov 07;[EPub Ahead of Print], G Garcia-Manero, NA Podoltsev, M Othus, JM Pagel, JP Radich, M Fang, DA Rizzieri, G Marcucci, SA Strickland, MR Litzow, ML Savoie, BC Medeiros, MA Sekeres, TL Lin, GL Uy, BL Powell, JE Kolitz, RA Larson, RM Stone, D Claxton, J Essell, SM Luger, SR Mohan, A Moseley, FR Appelbaum, HP ErbaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.